AngioDynamics Announces Live Broadcast of ELVS Procedure at ISET Meeting
AngioDynamics Announces Live Broadcast of ELVS Procedure at ISET Meeting
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Jan. 29, 2004--AngioDynamics, Inc., a wholly-owned subsidiary of E-Z-EM, Inc., today announced that a live demonstration of its ELVS endovascular laser treatment system will be broadcast to the 16th Annual International Symposium on Endovascular Therapy (ISET) in Miami, Florida on Thursday, January 29 at 3 p.m. EST. The case will be performed by interventional radiologist James F. Benenati, M.D., and moderated by Alex Powell, M.D. The demonstration case will be performed at Miami Cardiac & Vascular Institute and will be broadcast live into the Conference center in the Fontainebleau Hilton Hotel in Miami.
Endovascular laser venous system procedures are a less invasive alternative to vein stripping for the treatment of venous insufficiency of the greater saphenous vein. Vein stripping is a lengthy, painful and traumatic surgical procedure that involves significant patient recovery time. In contrast, laser treatment is an outpatient procedure that allows the patient to immediately return to normal activities with no scarring and minimal post-operative pain. The laser delivers energy that causes the degenerating vein to collapse while the body routes the blood to other veins. Another treatment alternative to laser treatment is radio frequency ablation, which we believe is a more time consuming and expensive procedure than laser treatment.
Commenting for AngioDynamics, David Doster, Product Manager for the ELVS Laser, said, "This demonstration represents a great learning opportunity for physicians interested in treatment options for severe varicose veins."
For additional information on the ELVS System, contact David Doster at 1-800-772-6446, ext. 126, Email: ddoster@angiodynamics.com or visit the ELVS Laser web site at www.elvslaser.com.
ELVS is a trademark of Biolitec, Inc.
About AngioDynamics
AngioDynamics, Inc. (www.angiodynamics.com) manufactures a wide range of products, including angiographic, dialysis, PTA dilation, thrombolytic, image-guided vascular access, endovascular laser venous system, as well as abdominal infection drainage products. AngioDynamics' focus is on therapeutic products that enable interventional physicians to treat peripheral vascular diseases and other non-coronary diseases.
About E-Z-EM
E-Z-EM is the world's largest manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation, the EmpowerCT® with patented EDA technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system. For additional information, please contact Tom Johnson at 1-800-544-4624, ext. 3317 (E-mail: tjohnson@ezem.com) or visit our corporate web site at www.ezem.com.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the outcome of the Diomed patent litigation, the ability of the Company to develop its products, market acceptance of virtual colonoscopy as a new imaging procedure, market acceptance of the ELVS system, the size and quantity of orders for RSDL, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended November 29, 2003, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company.
Contact:
E-Z-EM, Inc.
Tom Johnson, 800-544-4624, ext. 3317
www.ezem.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
212-838-3777
Bruce Voss (bvoss@lhai.com)
310-691-7100
